Analyse Rapport Therapeutics, Inc. (RAPP) — Kairos Score 47/100

À propos de Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

17 transactions — 0 achats et 17 ventes déclarés par les dirigeants de Rapport Therapeutics, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur RAPP dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur RAPP.

• The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
• The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.